Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
3TC (Lamivudine; GR109714X) Open-Label Program
This study has been completed.
Sponsored by: | Glaxo Wellcome |
---|---|
Information provided by: | AIDS Clinical Trials Information Service |
Purpose
To make lamivudine (3TC) available to patients with progressive, symptomatic HIV disease who cannot participate in a controlled clinical trial and who are refractory or unable to tolerate other therapies. To collect data pertaining to the safety of 3TC at two dose levels. To evaluate the effect of 3TC on markers of hepatitis B in co-infected patients at five to ten selected sites.
Condition | Treatment or Intervention |
---|---|
HIV Infections |
Drug: Lamivudine Drug: Zidovudine |
MedlinePlus related topics: AIDS
Study Type: Interventional
Study Design: Treatment, Open Label, Safety Study
Patients 12 years and older are randomized to receive one of two doses of 3TC for a duration determined by the patient's physician or until termination of the program. Patients < 12 years receive a lower dose of 3TC. Patients are followed monthly. For selected sites only, serum samples are collected every 3 months from patients identified as HBsAg positive. PER 02/28/95 AMENDMENT: Patients enrolled prior to 3/1/95 may remain on their assigned monotherapy dose or change to combination therapy with 3TC and zidovudine.
Eligibility
Ages Eligible for Study: 3 Years and above, Genders Eligible for Study: Both
Criteria
Patients must:
Location Information
More Information
Publications
Pluda J, Cooley T, Montaner J, McCaffrey R, Wainberg M, Yarchoan R. Phase I/II study of 3TC (GR109714X) in adults with ARC or AIDS. Int Conf AIDS. 1993 Jun 6-11;9(1):69 (abstract no WS-B26-2)
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |